Ramadhani Salum Chambuso

Dr. Ramadhani Salum Chambuso

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2025 in One Health
Verified
Journal Article
Open access
ABAmjad Banibella
Amjad Banibella
NSNooruldeen Saad
Nooruldeen Saad
JEJafar Eyad
Jafar Eyad
RCRamadhani Salum Chambuso
Ramadhani Salum Chambuso
We investigated multi-laboratory culture records to quantify AMR profiles for Salmonella infections, diagnostic gaps and challenges in Nigeria. Using a retrospective study, we analyzed a total of 84,548 culture results from 26,630 patients across 25 public laboratories participated in the AMR surveillance report from Nigeria. Salmonella species and stool culture positivity rates were compared throughout the 3 year-period. Stool sampling gaps were quantified and Salmonella species AMR for key antibiotic classes were assessed. Chi-square test and Wald risk ratios were used for statistical analysis, a p-value of <0.05 was considered statistically significant. Out of 84,548 culture results, a total of 621 Salmonella species were isolated with Salmonella Typhi being the most commonly reported species. Stool samples represented only 3 % of all collected specimens, yet Salmonella species culture positivity increased from 64 % to 97 % (2016 to 2017; RR 1.51, 95 % CI 1.37–1.65, p < 0.001). AMR remained entrenched: trimethoprim–sulfamethoxazole ≥90%, fluoroquinolones ≥69 %, and nalidixic acid 91 %; cephalosporin resistance climbed from 60 % to 88 %. We identified a limited stool collection compared to other samples, which impacted identification of Salmonella infections in an endemic area like Nigeria. The key barriers were limited laboratory data integration and lack of One Health surveillance which amplified Salmonella infections AMR threat. Limited stool culture and escalating multi-drug resistance jeopardize the empirical therapy for Salmonella infections. Our study offers immediate, scalable interventions to strengthen One-Health Salmonella infections AMR control in Nigeria.

7 December 2024 in Journal of the National Cancer Center
Verified
Journal Article
Open access
RCRamadhani Salum Chambuso
Ramadhani Salum Chambuso
SMStephene S Meena
Stephene S Meena
Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) predisposition syndrome, characterized by a high mutational burden and microsatellite instability-high (MSI-H) tumors. Immunology of LS-associated CRC (LS-CRC) is unique, with significant implications for treatment. Despite well-established knowledge of LS immunology, immunotherapy dose and treatment response can vary significantly based on local tumor immunity and specific germline pathogenic variant of LS genes. This variability necessitates tailored surveillance strategies and new personalised immunotherapy approaches for LS patients. LS-CRC often benefits from immunotherapy due to the distinct tumor microenvironment (TME) and the variety of tumor infiltrating lymphocytes (TILs). This perspective discusses a novel approach of analysing spatial TILs at a single-cell level using tumor whole slide images (WSIs) that accounts for the distinct TME of LS-CRC. By emphasizing the necessity of personalized medicine in hereditary cancer syndromes, the future research and clinical practices that enhance patient outcomes through precision oncology is inspired.

27 January 2025 in npj Vaccines
Verified
Journal Article
Open access
PDF file
SMStephene Shadrack Meena
Stephene Shadrack Meena
BKBenson K. Kosgei
Benson K. Kosgei
GSGeofrey F. Soko
Geofrey F. Soko
CTCheng Tingjun
Cheng Tingjun
RCRamadhani Salum Chambuso
Ramadhani Salum Chambuso
RHRay P.S. Han
Ray P.S. Han
Tumor-derived exosomes (TDEs) mediate oncogenic communication, which modifies target cells to reinforce a tumor-promoting microenvironment. TDEs support cancer progression by suppressing anti-tumor immune responses, promoting metastasis, and conferring drug resistance. Thus, targeting TDEs could improve the efficacy of anti-cancer treatments and control metastasis. Current strategies to inhibit TDE-mediated oncogenic communication including drug-based and genetic modification-based inhibition of TDE release and/or uptake, have proved to be inefficient. In this work, we propose TDE surface engineering to express foreign antigens that will trigger life-long anti-TDE immune responses. The possibility of combining the anti-TDE vaccines with other treatments such as chemotherapy, radiotherapy, targeted therapy, and surgery is also explored.

2 February 2023 in Cells
Verified
Journal Article
Open access
PDF file
RCRamadhani Salum Chambuso
Ramadhani Salum Chambuso
MMMbalenhle Mthembu
Mbalenhle Mthembu
EKEveline Kaambo
Eveline Kaambo
BRBarbara Robertson
Barbara Robertson
RRRaj Ramesar
Raj Ramesar
Lynch syndrome (LS) is an inherited disorder in which affected individuals have a significantly higher-than-average risk of developing colorectal and non-colorectal cancers, often before the age of 50 years. In LS, mutations in DNA repair genes lead to a dysfunctional post-replication repair system. As a result, the unrepaired errors in coding regions of the genome produce novel proteins, called neoantigens. Neoantigens are recognised by the immune system as foreign and trigger an immune response. Due to the invasive nature of cancer screening tests, universal cancer screening guidelines unique for LS (primarily colonoscopy) are poorly adhered to by LS variant heterozygotes (LSVH). Currently, it is unclear whether immunogenomic components produced as a result of neoantigen formation can be used as novel biomarkers in LS. We hypothesise that: (i) LSVH produce measurable and dynamic immunogenomic components in blood, and (ii) these quantifiable immunogenomic components correlate with cancer onset and stage. Here, we discuss the feasibility to: (a) identify personalised novel immunogenomic biomarkers and (b) validate these biomarkers in various clinical scenarios in LSVH.

12 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RCRamadhani Salum Chambuso
Ramadhani Salum Chambuso
BRBarbara Robertson
Barbara Robertson
RRRaj Ramesar
Raj Ramesar
Identification of germline pathogenic variants (PV) predisposing to Lynch syndrome (LS) is an important step for effective use of cascade screening of extended at-risk lineages, leading to reduced morbidity and mortality due to colorectal cancer (CRC). As a general rule, however, next generation sequencing (NGS, either of gene panels or whole exomes) is relatively expensive and unaffordable for general clinical use. In resource-poor settings, performing NGS testing on an entire cohort of CRC patients, even if limited to those under 50 or 60 years of age, still places an enormous burden on limited resources. Although family history can be a good indicator for LS testing, identifying at-risk family members and offering cascade screening may not benefit many patients/probands without an obvious family history. This article presents a novel program called Modified Ascertainment and follow-up Program (MAP) with a scoring model for LS ascertainment and molecular screening by NGS with diagnosis confirmation of PV and cascade screening. The goal is to improve LS ascertainment in light of the growing burden of early-onset CRC, particularly in low- and middle-income countries. Through MAP, judiciously applied molecular genetics will improve identification of PV predisposing to LS and cascade screening.